This text is a result of machine translation.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Yingkang life: it is expected to lose 300 million yuan to 370 million yuan in 2021
The coal sector fell sharply at the opening, and Shanghai Energy fell by the limit
Saudi Arabia's Vision 2030: Foreign Investment Bidding Landscape, Risks, and Opportunities
"The Stone Age didn’t end for lack of stone, and the oil age will end long before the world runs out of oil." — Sheikh Ahmed Zaki Yamani, Saudi Oil Minister during the reign of King Faisal
Oct 25, 2024 10:31 PM
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
Defining key tasks and accelerating the construction of new urbanization
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
Saudi Arabia's Vision 2030: Foreign Investment Bidding Landscape, Risks, and Opportunities
Oct 25, 2024 10:31 PM
Chinese tea beverages are experiencing a resurgence in Thailand
Oct 21, 2024 02:52 PM
How Can Solar Companies Seize Opportunities in the Post-Subsidy Era?
Oct 10, 2024 05:23 PM